Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease

Expert Opinion on Investigational Drugs

Volumn 14, Issue 11, 2005, Pages 1385-1409

  Beher, Dirk ^a   Graham, Samuel L ^b  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

secretase; secretase; A ; Alzheimer's disease; Aspartyl protease; BACE; NSAID

Indexed keywords

ALDEHYDE DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BENZODIAZEPINE DERIVATIVE; BETA SECRETASE; BETA SECRETASE INHIBITOR; BMS 299897; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPEPTIDE DERIVATIVE; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GMS 299897; HEPARAN SULFATE; IBUPROFEN; INDOMETACIN; LEVO FLURBIPROFEN; LOW MOLECULAR WEIGHT HEPARIN; LY 411575; LY 450139; MW 167; MW 936; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PROTEINASE INHIBITOR; SULFONE DERIVATIVE; SULINDAC SULFIDE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; CATALYSIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; IC 50; MEDICAL DECISION MAKING; NONHUMAN; ONCOLOGY; PHENOTYPE; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; TREATMENT PLANNING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTIC ENDOPEPTIDASES; ENDOPEPTIDASES; HUMANS; PROTEASE INHIBITORS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 27744480831     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.11.1385     Document Type: Review

References (263)

1. HY LX, KELLER DM: Prevalence of AD among whites: a summary by levels of severity. Neurology (2000) 55(2):198-204.
2. GOEDERT M, WISCHIK CM, CROWTHER RA, WALKER JE, KLUG A: Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer's disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA (1988) 85(11):4051-4055.
3. GOEDERT M, SISODIA SS, PRICE DL: Neurofibrillary tangles and β-amyloid deposits in Alzheimer's disease. Curr. Opin. Neurobiol. (1991) 1(3):441-447.
4. GLENNER GG, WONG CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. (1984) 120(3):885-890.
5. MASTERS CL, SIMMS G, WEINMAN NA et al.: Amyloid plaque core protein in Alzheimer's disease and Down's syndrome. Proc. Natl. Acad. Sci. USA (1985) 82(12):4245-4249.
6. KANG J, LEMAIRE HG, UNTERBECK A et al.: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 325(6106):733-736.
7. HAASS C, SCHLOSSMACHER MG, HUNG AY et al.: Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature (1992) 359(6393):322-325.
8. SPILLANTINI MG, MURRELL JR, GOEDERT M et al.: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA (1998) 95(13):7737-7741.
9. HUTTON M, LENDON CL, RIZZU P et al.: Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 393(6686):702-705.
10. ODDO S, CACCAMO A, SHEPHERD JD et al.: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron (2003) 39(3):409-421.
11. ODDO S, BILLINGS L, KESSLAK JP. CRIBBS DH, LAFERLA FM: Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 43(3):321-332.
12. HARDY JA, HIGGINS GA: Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 256(5054):184-185.
13. MULLAN M, CRAWFORD F, AXELMAN K et al.: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat. Genet. (1992) 1(5):345-347.
14. GOATE A, CHARTIER-HARLIN MC, MULLAN M et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349(6311):704-706.
15. MURRELL J, FARLOW M, GHETTI B, BENSON MD: A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (1991) 254(5028):97-99.
16. NARUSE S, IGARASHI S, KOBAYASHI H et al.: Mis-sense mutation Val-Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease. Lancet (1991) 337(8747):978-979.
17. ROGAEV EI, SHERRINGTON R, ROGAEVA EA et al.: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature (1995) 376(6543):775-778.
18. SHERRINGTON R, ROGAEV EI, LIANG Y et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 375(6534):754-760.
19. LEVY-LAHAD E, WASCO W, POORKAJ P et al.: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 269(5226):973-977.
20. LEVY-LAHAD E, WIJSMAN EM, NEMENS E et al.: A familial Alzheimer's disease locus on chromosome 1. Science (1995) 269(5226):970-973.
21. HARDY J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. (1997) 20(4):154-159.
22. HARDY J: The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc. Natl. Acad. Sci. USA (1997) 94(6):2095-2097.
23. LAMBERT MP, BARLOW AK, CHROMY BA et al.: Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA (1998) 95(11):6448-6453.
24. KLEIN WL: Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. (2002) 41(5):345-352.
25. GONG Y, CHANG L, VIOLA KL et al.: Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA (2003) 100(18):10417-10422.
26. TANZI RE, BERTRAM L: Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 120(4):545-555.
27. LEISSRING MA, FARRIS W, CHANG AY et al.: Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 40(6):1087-1093.
28. IWATA N, TSUBUKI S, TAKAKI Y et al.: Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. (2000) 6(2):143-150.
29. DEMATTOS RB, BALES KR, CUMMINS DJ et al.: Peripheral anti-Aβ antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA (2001) 98(15):8850-8855.
30. CITRON M, OLTERSDORF T, HAASS C et al.: Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature (1992) 360(6405):672-674.
31. NEVE RL, FINCH EA, DAWES LR: Expression of the Alzheimer amyloid precursor gene transcripts in the human brain. Neuron (1988) 1(8):669-677.
32. SPILLANTINI MG, HUNT SP, ULRICH J, GOEDERT M: Expression and cellular localization of amyloid β-protein precursor transcripts in normal human brain and in Alzheimer's disease. Brain Res. Mol. Brain Res. (1989) 6(2-3):143-150.
33. HEBERT SS, SERNEELS L, DEJAEGERE T et al.: Coordinated and widespread expression of γ-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol. Dis. (2004) 17(2):260-272.
34. VASSAR R, BENNETT BD, BABU-KHAN S et al.: β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 286(5440):735-741.
35. GHISO J, MATSUBARA E, KOUDINOV A et al.: The cerebrospinal-fluid soluble form of Alzheimer's amyloid β is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. (1993) 293(Part 1):27-30.
36. DEMATTOS RB, CIRRITO JR, PARSADANIAN M et al.: ApoE and clusterin cooperatively suppress Aβ levels and deposition. Evidence that ApoE regulates extracellular Aβ metabolism in vivo. Neuron (2004) 41(2):193-202.
37. BRIGHTMAN MW, REESE TS: Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. (1969) 40(3):648-677.
38. CSERR HF, BUNDGAARD M: Blood-brain interfaces in vertebrates: a comparative approach. Am. J. Physiol. (1984) 246(3 Part 2):R277-R288.
39. ZLOKOVIC BV: Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. (2005) 28(4):202-208.
40. DEANE R, WU Z, SAGARE A et al.: LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron (2004) 43(3):333-344.
41. DEANE R, DU YS, SUBMAMARYAN RK et al.: RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. (2003) 9(7):907-913.
42. ZLOKOVIC BV, MARTEL CL, MATSUBARA E et al.: Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. USA (1996) 93(9):4229-4234.
43. GAMES D, ADAMS D, ALESSANDRINI R et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature (1995) 373(6514):523-527.
44. HSIAO K, CHAPMAN P, NILSEN S et al.: Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science (1996) 274(5284):99-102.
45. KAWARABAYASHI T, YOUNKIN LH, SAIDO TC et al.: Age-dependent changes in brain, CSF, and plasma amyloid (β) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. (2001) 21(2):372-381.
46. SAVAGE MJ, TRUSKO SP, HOWLAND DS et al.: Turnover of amyloid β-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci. (1998) 18(5):1743-1752.
47. BARTEN DM, GUSS VL, CORSA JA et al.: Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor. J. Pharmacol. Exp. Ther. (2005) 312(2):635-643.
48. HOLCOMB L, GORDON MN, McGOWAN E et al.: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. (1998) 4(1):97-100.
49. JOHNSON-WOOD K, LEE M, MOTTER R et al.: Amyloid precursor protein processing and A β42 deposition in a transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1997) 94(4):1550-1555.
50. CIRRITO JR, MAY PC, O'DELL MA et al.: In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. (2003) 23(26):8844-8853.
51. LAMB BT, SISODIA SS, LAWLER AM et al.: Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice. Nat. Genet. (1993) 5(1):22-30.
52. ANDERSON JJ, HOLTZ G, BASKIN PP et al.: Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Pharmacol. (2005) 69(4):689-698.
53. BEST JD, JAY MT, OTU F et al.: Quantitative measurement of changes in amyloid-β(40) in the rat brain and cerebrospinal fluid following treatment with the γ-secretase inhibitor LY-411575 [N2- [(2S)-2-(3,5-difluorophenyl)-2- hydroxyethanoyl]-N1-[(7S)-5-methyl-6- oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J. Pharmacol. Exp. Ther. (2005) 313(2):902-908.
54. GRIMWOOD S, HOGG J, JAY MT et al.: Determination of guinea-pig cortical γ-secretase activity ex vivo following the systemic administration of a γ-secretase inhibitor. Neuropharmacology (2005) 48(7):1002-1011.
55. LANZ TA, HOSLEY JD, ADAMS WJ, MERCHANT KM: Studies of Aβ pharmacodynamics in the brain, CSF and plasma in young (plaque-free) Tg2576 mice using the γ-secretase inhibitor, LY-411575. J. Pharmacol. Exp. Ther. (2004) 309(1):49-55.
56. ANDREASEN N, MINTHON L, VANMECHELEN E et al.: Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. (1999) 273(1):5-8.
57. ANDREASEN N, HESSE C, DAVIDSSON P et al.: Cerebrospinal fluid β-amyloid(1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer's disease and stability during the course of disease. Arch. Neurol. (1999) 56(6):673-680.
58. ANDREASEN N, BLENNOW K: CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin. Neurol. Neurosurg. (2005) 107(3):165-173.
59. WOLFE MS, XIA W, OSTASZEWSKI BL et al.: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature (1999) 398(6727):513-517.
60. WEIHOFEN A, BINNS K, LEMBERG MK, ASHMAN K, MARTOGLIO B: Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science (2002) 296(5576):2215-2218.
61. RAWSON RB, ZELENSKI NG, NIJHAWAN D et al.: Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. Mol. Cell (1997) 1(1):47-57.
62. URBAN S, LEE JR, FREEMAN M: Drosophila rhomboid-1 defines a family of putative intramembrane scrine proteases. Cell (2001) 107(2):173-182.
63. OKOCHI M, STEINER H, FUKUMORI A et al.: Presenilins mediate a dual intramembranous γ-secretase cleavage of Notch-1. EMBO J. (2002) 21(20):5408-5416.
64. SASTRE M, STEINER H, FUCHS K et al.: Presenilin-dependent γ-secretase processing of β-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. (2001) 2:835-841.
65. WEIDEMANN A, EGGERT S, REINHARD FB et al.: A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry (2002) 41(8):2825-2835.
66. FUNAMOTO S, MORISHIMA-KAWASHIMA M, TANIMURA Y et al.: Truncated carboxyl-terminal fragments of β-amyloid precursor protein are processed to amyloid β-proteins 40 and 42. Biochemistry (2004) 43(42):13532-13540.
67. QI-TAKAHARA Y, MORISHIMA-KAWASHIMA M, TANIMURA Y et al.: Longer forms of amyloid β protein: implications for the mechanism of intramembrane cleavage by γ-secretase. J. Neurosci. (2005) 25(2):436-445.
68. WANG R, MESCHIA JF, COTTER RJ, SISODIA SS: Secretion of the β/A4 amyloid precursor protein. Identification of a cleavage site in cultured mammalian cells. J. Biol. Chem. (1991) 266(25):16960-16964.
69. BEHER D, WRIGLEY JD, OWENS AP, SHEARMAN MS: Generation of C-terminally truncated amyloid-β peptides is dependent on γ-secretase activity. J. Neurochem. (2002) 82(3):563-575.
70. GU Y, MISONOU H, SATO T et al.: Distinct intramembrane cleavage of the β-amyloid precursor protein family resembling γ-secretase-like cleavage of Notch. J. Biol. Chem. (2001) 276(38):35235-35238.
71. WOLFE MS, XIA W, MOORE CL et al.: Peptidomimetic probes and molecular modeling suggest that Alzheimer's γ-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry (1999) 38(15):4720-4727.
72. SHEARMAN MS, BEHER D, CLARKE EE et al.: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry (2000) 39(30):8698-8704.
73. DE STROOPER B, SAFTIG P, CRAESSAERTS K et al.: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 391(6665):387-390.
74. LI YM, XU M, LAI MT et al.: Photoactivated γ-secretatase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 405:689-694.
75. ESLER WP, KIMBERLY WT, OSTASZEWSKI BL et al.: Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat. Cell Biol. (2000) 2:428-434.
76. SEIFFERT D, BRADLEY JD, ROMINGER CM et al.: Presenilin-1 and 2 are molecular targets for γ secretase inhibitors. J. Biol. Chem. (2000) 275:34086-34091.
77. WRIGLEY JD, NUNN EJ, NYABI O et al.: Conserved residues within the putative active site of γ-secretase differentially influence enzyme activity and inhibitor binding. J. Neurochem. (2004) 90(6):1312-1320.
78. RICHTER C, TANAKA T, YADA RY: Mechanism of activation of the gastric aspartic proteinases: pepsinogen, progastricsin and prochymosin. Biochem. J. (1998) 335(Part 3):481-490.
79. KNAPPENBERGER KS, TIAN G, YE X et al.: Mechanism of γ-secretase cleavage activation: is γ-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop? Biochemistry (2004) 43(20):6208-6218.
80. BEHER D, WRIGLEY JD, NADIN A et al.: Pharmacological knock-down of the presenilin 1 heterodimer by a novel γ-secretase inhibitor: implications for presenilin biology. J. Biol. Chem. (2001) 276(48):45394-45402.
81. ANNAERT WG, ESSELENS C, BAERT V et al.: Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron (2001) 32(4):579-589.
82. ESLER WP, KIMBERLY WT, OSTASZEWSKI BL et al.: Activity-dependent isolation of the presenilin-γ-secretase complex reveals nicastrin and a γ substrate. Proc. Natl. Acad. Sci. USA (2002) 99(5):2720-2725.
83. TIAN G, SOBOTKA-BRINER CD, ZYSK J et al.: Linear non-competitive inhibition of solubilized human γ-secretase by pepstatin A methylester, L-685458, sulfonamides and benzodiazepines. J. Biol. Chem. (2002) 277:31499-31505.
84. BEHER D, FRICKER M, NADIN A et al.: In vitro characterization of the presenilin-dependent γ-secretase complex using a novel affinity ligand. Biochemistry (2003) 42(27):8133-8142.
85. SHAH S, LEE SF, TABUCHI K et al.: Nicastrin functions as a γ-secretase-substrate receptor. Cell (2005) 122(3):435-447.
86. YU G, NISHIMURA M, ARAWAKA S et al.: Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature (2000) 407(6300):48-54.
87. GOUTTE C, TSUNOZAKI M, HALE VA, PRIESS JR: APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl. Acad. Sci. USA (2002) 99(2):775-779.
88. FRANCIS R, McGRATH G, ZHANG J et al.: Aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation. Dev. Cell (2002) 3(1):85-97.
89. EDBAUER D, WINKLER E, REGULA JT et al.: Reconstitution of γ-secretase activity. Nat. Cell Biol. (2003) 5(5):486-488.
90. TAKASUGI N, TOMITA T, HAYASHI I et al.: The role of presenilin cofactors in the γ-secretase complex. Nature (2003) 422(6930):438-441.
91. KIMBERLY WT, LAVOIE MJ, OSTASZEWSKI BL et al.: γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2. Proc. Natl. Acad. Sci. USA (2003) 42(22):6664-6673
92. WRIGLEY JD, SCHUROV I, NUNN EJ et al.: Functional overexpression of γ-secretase reveals protease-independent trafficking functions and a critical role of lipids for protease activity. J. Biol. Chem. (2005) 280(13):12523-12535.
93. HAASS C: Take five-BACE and the γ-secretase quartet conduct Alzheimer's amyloid β-peptide generation. EMBO J. (2004) 23(3):483-488.
94. HU Y, FORTINI ME: Different cofactor activities in γ-secretase assembly: evidence for a nicastrin-Aph-1 subcomplex. J. Cell Biol. (2003) 161(4):685-690.
95. LAVOIE MJ, FRAERING PC, OSTASZEWSKI BL et al.: Assembly of the γ-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J. Biol. Chem. (2003) 278(39):37213-37222.
96. KAETHER C, CAPELL A, EDBAUER D et al.: The presenilin C-terminus is required for ER-retention, nicastrin-binding and γ-secretase activity. EMBO J. (2004) 23(24):4738-4748.
97. DE STROOPER B: Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron (2003) 38(1):9-12.
98. SHIROTANI K, EDBAUER D, PROKOP S, HAASS C, STEINER H: Identification of distinct γ-secretase complexes with different APH-1 variants. J. Biol. Chem. (2004) 279(40):41340-41345.
99. LAI MT, CHEN E, CROUTHAMEL MC et al.: Presenilin-1 and presenilin-2 exhibit distinct yet overlapping γ-secretase activities. J. Biol. Chem. (2003) 278(25):22475-22481
100. MA G, LI T, PRICE DL, WONG PC: APH-1a is the principal mammalian APH-1 isoform present in γ-secretase complexes during embryonic development. J. Neurosci. (2005) 25(1):192-198.
101. SERNEELS L, DEJAEGERE T, CRAESSAERTS K et al.: Differential contribution of the three Aph1 genes to γ-secretase activity in vivo. Proc. Natl. Acad. Sci. USA (2005) 102(5):1719-1724.
102. MASTRANGELO P, MATHEWS PM, CHISHTI MA et al.: Dissociated phenotypes in presenilin transgenic mice define functionally distinct γ-secretases. Proc. Natl. Acad. Sci. USA (2005) 102(25):8972-8977.
103. LICHTENTHALER SF, WANG R, GRIMM H et al.: Mechanism of the cleavage specificity of Alzheimer's disease γ-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA (1999) 96(6):3053-3058.
104. BUXBAUM JD, LIU KN, LUO Y et al.: Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. (1998) 273(43):27765-27767.
105. POLLACK SJ, LEWIS H: Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr. Opin. Investig. Drugs (2005) 6(1):35-47.
106. SCHEINFELD MH, GHERSI E, LAKY K, FOWLKES BJ, D'ADAMIO L: Processing of β-amyloid precursor-like protein-1 and -2 by γ-secretase regulates transcription. J. Biol. Chem. (2002) 277(46):44195-44201.
107. EGGERT S, PALIGA K, SOBA P et al.: The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves α-, β-, γ-, and E-like cleavages. Modulation of APLP-1 processing by N-glycosylation. J. Biol. Chem. (2004) 279(18):18146-18156.
108. NI CY, MURPHY MP, GOLDE TE, CARPENTER G: γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 294(5549):2179-2181.
109. LEE HJ, JUNG KM, HUANG YZ et al.: Presenilin-dependent γ-secretase-like intramembrane cleavage of ErbB4. J. Biol. Chem. (2002) 277(8):6318-6323.
110. ANDERSSON CX, FERNANDEZ-RODRIGUEZ J, LAOS S et al.: Shedding and γ-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43. Biochem. J. (2005) 387(Part 2):377-384.
111. LAMMICH S, OKOCHI M, TAKEDA M et al.: Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Aβ-like peptide. J. Biol. Chem. (2002) 277(47):44754-44759.
112. SCHULZ JG, ANNAERT W, VANDEKERCKHOVE J et al.: Syndecan 3 intramembrane proteolysis is presenilin/γ-secretase-dependent and modulates cytosolic signaling. J. Biol. Chem. (2003) 278(49):48651-48657.
113. KIM DY, INGANO LA, KOVACS DM: Nectin-1α, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/γ-secretase-like cleavage. J. Biol. Chem. (2002) 277(51):49976-49981.
114. MARAMBAUD P, WEN PH, DUTT A et al.: A CBP binding transcriptional repressor produced by the PS1/E-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell (2003) 114(5):635-645.
115. MARAMBAUD P, SHIOI J, SERBAN G et al.: A presenilin-1/γ-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. (2002) 21(8):1948-1956.
116. TANIGUCHI Y, KIM SH, SISODIA SS: Presenilin-dependent 'γ-secretase' processing of deleted in colorectal cancer (DCC). J. Biol. Chem. (2003) 278(33):30425-30428.
117. JUNG KM, TAN S, LANDMAN N et al.: Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J. Biol. Chem. (2003) 278(43):42161-42169.
118. GOWRISHANKAR K, ZEIDLER MG, VINCENZ C: Release of a membrane-bound death domain by γ-secretase processing of the p75NTR homolog NRADD. J. Cell Sci. (2004) 117(Part 18):4099-4111.
119. HAMBSCH B, GRINEVICH V, SEEBURG PH, SCHWARZ MK: γ-Protocadherins, presenilin-mediated release of C-terminal fragment promotes locus expression. J. Biol. Chem. (2005) 280(16):15888-15897.
120. HAAS IG, FRANK M, VERON N, KEMLER R: Presenilin-dependent processing and nuclear function of γ-protocadherins. J. Biol. Chem. (2005) 280(10):9313-9319.
121. KIM DY, INGANO LA, CAREY BW, PETTINGELL WH, KOVACS DM: Presenilin/γ-secretase-mediated cleavage of the voltage-gated sodium channel β2-subunit regulates cell adhesion and migration. J. Biol. Chem. (2005) 280(24):23251-23261.
122. WONG HK, SAKURAI T, OYAMA F et al.: β Subunits of voltage-gated sodium channels are novel substrates of β-site amyloid precursor protein-cleaving enzyme (BACE1) and γ-secretase. J. Biol. Chem. (2005) 280(24):23009-23017.
123. COWAN JW, WANG Y, GUAN R et al.: Growth hormone receptor is a target for presenilin-dependent γ-secretase cleavage. J. Biol. Chem. (2005) 280(19):19331-19342.
124. MAY P, REDDY YK, HERZ J: Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J. Biol. Chem. (2002) 277(21):18736-18743.
125. DE STROOPER B, ANNAERT W, CUPERS P et al.: A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 398(6727):518-522.
126. SIX E, NDIAYE D, LAABI Y et al.: The Notch ligand E1 is sequentially cleaved by an ADAM protease and γ-secretase. Proc. Natl. Acad. Sci. USA (2003) 100(13):7638-7643.
127. LAVOIE MJ, SELKOE DJ: The Notch ligands, Jagged and E, are sequentially processed by α-secretase and presenilin /γ-secretase and release signaling fragments. J. Biol. Chem. (2003) 278(36):34427-34437.
128. KOPAN R, SCHROETER EH, WEINTRAUB H, NYE JS: Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc. Natl. Acad. Sci. USA (1996) 93(4):1683-1688.
129. SCHROETER EH, KISSLINGER JA, KOPAN R: Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature (1998) 393(6683):382-386.
130. MUMM JS, SCHROETER EH, SAXENA MT et al.: A ligand-induced extracellular cleavage regulates γ-secretase-like proteolytic activation of Notch1. Mol. Cell (2000) 5(2):197-206.
131. BROU C, LOGEAT F, GUPTA N et al.: A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell (2000) 5(2):207-216.
132. ARTAVANIS-TSAKONAS S, MATSUNO K, FORTINI ME: Notch signaling. Science (1995) 268(5208):225-232.
133. WASHBURN T, SCHWEIGHOFFER E, GRIDLEY T et al.: Notch activity influences the αβ versus γδ T cell lineage decision. Cell (1997) 88(6):833-843.
134. FRE S, HUYGHE M, MOURIKIS P et al.: Notch signals control the fate of immature progenitor cells in the intestine. Nature (2005) 435(7044):964-968.
135. HARRISON T, BEHER D: γ-Secretase inhibitors-from molecular probes to new therapeutics? Prog. Med. Chem. (2003) 41:99-127.
136. HARRISON T, CHURCHER I, BEHER D: γ-Secretase as a target for drug intervention in Alzheimer's disease. Curr. Opin. Drug Discov. Devel. (2004) 7(5):709-719.
137. HIGAKI J, QUON D, ZHONG Z, CORDELL B: Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron (1995) 14(3):651-659.
138. WOLFE MS, CITRON M, DIEHL TS et al.: A substrate-based difluoro ketone selectively inhibits Alzheimer's γ-secretase activity. J. Med. Chem. (1998) 41(1):6-9.
139. TEALL M, OAKLEY P, HARRISON T et al.: Aryl sulfones: a new class of γ-secretase inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(10):2685-2688.
140. CHURCHER I, WILLIAMS S, KERRAD S et al.: Design and synthesis of highly potent benzodiazepine γ-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl) -4-hydroxy-N-((3S)-1-methyl-2-oxo-5-phenyl-2, 3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement. J. Med. Chem. (2003) 46(12):2275-2278.
141. NESS D, BOGGS LN, HEPBURN D et al.: Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol. Aging (2004) 25(Suppl. 2):S238.
142. DOVEY HF, JOHN V, ANDERSON JP et al.: Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J. Neurochem. (2001) 76(1):173-181.
143. LANZ TA, HIMES CS, PALLANTE G et al.: The γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L -alanyll-S-phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharmacol. Exp. Ther. (2003) 305(3):864-871.
144. LEWIS HD, PEREZ REVUELTA BI, NADIN A et al.: Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and β-APP cleavages. Biochemistry (2003) 42(24):7580-7586.
145. WONG GT, MANFRA D, POULET FM et al.: Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits Aβ production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. (2004) 279(13):12876-12882.
146. SEARFOSS GH, JORDAN WH, CALLIGARO DO et al.: Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J. Biol. Chem. (2003) 278(46):46107-46116.
147. SIEMERS E, SKINNER M, DEAN RA et al.: Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers. Clin. Neuropharmacol. (2005) 28(3):126-132.
148. WONG PC, ZHENG H, CHEN H et al.: Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature (1997) 387(6630):288-292.
149. SHEN J, BRONSON RT, CHEN DF et al.: Skeletal and CNS defects in presenilin-1-deficient mice. Cell (1997) 89(4):629-639.
150. GELING A, STEINER H, WILLEM M, BALLY-CUIF L, HAASS C: A γ-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep. (2002) 3(7):688-694.
151. MICCHELLI CA, ESLER WP, KIMBERLY WT et al.: γ-Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J. (2003) 17(1):79-81.
152. RADTKE F, WILSON A, MacDONALD HR: Notch signaling in T- and B-cell development. Curr. Opin. Immunol. (2004) 16(2):174-179.
153. RADTKE F, WILSON A, MANCINI SJ, MacDONALD HR: Notch regulation of lymphocyte development and function. Nat. Immunol. (2004) 5(3):247-253.
154. DOERFLER P, SHEARMAN MS, PERLMUTTER RM: Presenilin-dependent γ-secretase activity modulates thymocyte development. Proc. Natl. Acad. Sci. USA (2001) 98(16):9312-9317.
155. HADLAND BK, MANLEY NR, SU D et al.: γ-secretase inhibitors repress thymocyte development. Proc. Natl. Acad. Sci. USA (2001) 98(13):7487-7491.
156. MILANO J, McKAY J, DAGENAIS C et al.: Modulation of notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. (2004) 82(1):341-358.
157. SAITO T, CHIBA S, ICHIKAWA M et al.: Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity (2003) 18(5):675-685.
158. KURODA K, HAN H, TANI S et al.: Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity (2003) 18(2):301-312.
159. TANIGAKI K, HAN H, YAMAMOTO N et al.: Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat. Immunol. (2002) 3(5):443-450.
160. JENSEN J, PEDERSEN EE, GALANTE P et al.: Control of endodermal endocrine development by Hes-1. Nat. Genet. (2000) 24(1):36-44.
161. VAN ES JH, VAN GIJN ME, RICCIO O et al.: Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature (2005) 435(7044):959-963.
162. ELLISEN LW, BIRD J, WEST DC et al.: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell (1991) 66(4):649-661.
163. WENG AP, FERRANDO AA, LEE W et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306(5694):269-271.
164. UYTTENDAELE H, MARAZZI G, WU G et al.: Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development (1996) 122(7):2251-2259.
165. DAS I, CRAIG C, FUNAHASHI Y et al.: Notch oncoproteins depend on γ-secretase/presenilin activity for processing and function. J. Biol. Chem. (2004) 279(29):30771-30780.
166. PECE S, SERRESI M, SANTOLINI E et al.: Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J. Cell Biol. (2004) 167(2):215-221.
167. GUO M, JAN LY, JAN YN: Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Neuron (1996) 17(1):27-41.
168. RHYU MS, JAN LY, JAN YN: Asymmetric distribution of numb
169. PARIS D, QUADROS A, PATEL N et al.: Inhibition of angiogenesis and tumor growth by β and γ-secretase inhibitors. Eur. J. Pharmacol. (2005) 514(1):1-15.
170. CURRY CL, REED LL, GOLDE TE et al.: γ-Secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene (2005) 24(42):6333-6344.
171. WEIJZEN S, RIZZO P, BRAID M et al.: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. (2002) 8(9):979-986.
172. WEGGEN S, ERIKSEN JL, DAS P et al.: A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature (2001) 414(6860):212-216.
173. STEWART WF, KAWAS C, CORRADA M, METTER EJ: Risk of Alzheimer's disease and duration of NSAID use. Neurology (1997) 48(3):626-632.
174. ERIKSEN JL, SAGI SA, SMITH TE et al.: NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ 42 in vivo. J. Clin. Invest. (2003) 112(3):440-449.
175. MOORE CL, LEATHERWOOD DD, DIEHL TS, SELKOE DJ, WOLFE MS: Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's γ-secretase: implications for inhibitor design. J. Med. Chem. (2000) 43(18):3434-3442.
176. WEGGEN S, ERIKSEN JL, SAGI SA et al.: Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β 42 production by direct modulation of γ-secretase activity. J. Biol. Chem. (2003) 278(34):31831-31837.
177. SAGI SA, WEGGEN S, ERIKSEN J, GOLDE TE, KOO EH: The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of κB kinase, and NF κB, do not reduce amyloid β 42 production. J. Biol. Chem. (2003) 278(34):31825-31830.
178. ZHOU Y, SU Y, LI B et al.: Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho. Science (2003) 302(5648):1215-1217.
179. KUKAR T, MURPHY MP, ERIKSEN JL et al.: Diverse compounds mimic Alzheimer's disease-causing mutations by augmenting Aβ42 production. Nat. Med. (2005) 11(5):545-550.
180. TAKAHASHI Y, HAYASHI I, TOMINARI Y et al.: Sulindac sulfide is a noncompetitive γ-secretase inhibitor that preferentially reduces Aβ 42 generation. J. Biol. Chem. (2003) 278(20):18664-18670.
181. BEHER D, CLARKE EE, WRIGLEY JD et al.: Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. (2004) 279(42):43419-43426.
182. FRAERING PC, YE W, STRUB JM et al.: Purification and characterization of the human γ-secretase complex. Biochemistry (2004) 43(30):9774-9789.
183. LLEO A, BEREZOVSKA O, HERL L et al.: Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation. Nat. Med. (2004) 10(10):1065-1066.
184. WAGNER SL, KOUNNAS MZ, TYREE CM et al.: Modulators of γ-secretase activity that lower Aβ-42 levels without affecting Notch proteolytic processing. 7th International Conference AD /PD, Sorrento, Italy (2005):11.
185. SINHA S, ANDERSON JP, BARBOUR R et al.: Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature (1999) 402(6761):537-540.
186. HUSSAIN I, POWELL D, HOWLETT DR et al.: Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol. Cell Neurosci. (1999) 14(6):419-427.
187. LIN X, KOELSCH G, WU S et al.: Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. Proc. Natl. Acad. Sci. USA (2000) 97(4):1456-1460.
188. SAUNDERS AJ, KIM T-W, TANZI RE: BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down's syndrome region of chromosome 21. Science (1998) 286:1255a.
189. YAN R, BIENKOWSKI MJ, SHUCK ME et al.: Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature (1999) 402(6761):533-537.
190. FARZAN M, SCHNITZLER CE, VASILIEVA N, LEUNG D, CHOE H: BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc. Natl. Acad. Sci. USA (2000) 97(17):9712-9717.
191. JOHN V, BECK JP, BIENKOWSKI MJ, SINHA S, HEINRIKSON RL: Human β-secretase (BACE) and BACE inhibitors. J. Med. Chem. (2003) 46(22):4625-4630.
192. CITRON M: b-Secretase inhibition for the treatment of Alzheimer's disease - promise and challenge. Trends Pharmacol. Sci. (2004) 25(2):92-97.
193. HOLSINGER R, McLEAN C, BEYREUTHER K, MASTERS C, EVIN G: Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann. Neurol. (2002) 51(6):783-786.
194. FUKUMOTO H, ROSENE DL, MOSS MB et al.: b-secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol. (2004) 164(2):719-725.
195. LI R, LINDHOLM K, YANG L-B et al.: Amyloid β peptide load is correlated with increased b-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. USA (2004) 101(10):3632-3637.
196. TYLER SJ, DAWBARN D, WILCOCK GK, ALLEN SJ: α- and β-secretase: profound changes in Alzheimer's disease. Biochem. Biophys. Res. Commun. (2002) 299(3):373-376.
197. YANG L, LINDHOLM K, YAN R et al.: Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer's disease. Nat. Med. (2003) 9(1):3-4.
198. HOLSINGER R, McLEAN C, COLLINS S, MASTERS C, EVIN G: Increased β-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann. Neurol. (2004) 55(6):898-899.
199. TAMAGNO E, PAROLA M, BARDINI P et al.: β-Site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. (2005) 92(3):628-636.
200. LEUBA G, WERNLI G, VERNEY A et al.: Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. (2005) 19(4):171-183.
201. ROSSNER S, LANGE DOHNA C, ZEITSCHEL U, PEREZ POLO JR: Alzheimer's disease β-secretase BACE1 is not a neuron-specific enzyme. J. Neurochem. (2005) 92(2):226-234.
202. CAI H, WANG Y, McCARTHY D et al.: BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. (2001) 4(3):233-234.
203. LUO Y, BOLON B, KAHN S et al.: Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci. (2001) 4(3):231-232.
204. HARRISON SM, HARPER AJ, HAWKINS J et al.: BACE1 (β-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. (2003) 24(3):646-655.
205. OHNO M, SAMETSKY E, YOUNKIN L et al.: BACE1 Deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron (2004) 41(1):27-33.
206. KAMENETZ F, TOMITA T, HSIEH H et al.: APP processing and synaptic function. Neuron (2003) 37(6):925-937.
207. DOMINGUEZ D, TOURNOY J, HARTMANN D et al.: Phenotypical and biochemical analysis of BACE1 and BACE2 deficient mice. J. Biol. Chem. (2005) 280(35):30797-30806.
208. CHIOCCO MJ, KULNANE LS, YOUNKIN L et al.: Altered amyloid-β metabolism and deposition in genomic-based β-secretase transgenic mice. J. Biol. Chem. (2004) 279(50):52535-52542.
209. MOHAJERI MH, SAINI KD, NITSCH RM: Transgenic BACE expression in mouse neurons accelerates amyloid plaque pathology. J. Neural. Trans. (2004) 111(3):413-425.
210. BODENDORF U, DANNER S, FISCHER F et al.: Expression of human β-secretase in the mouse brain increases the steady-state level of β-amyloid. J. Neurochem. (2002) 80(5):799-806.
211. HANIU M, DENIS P, YOUNG Y et al.: Characterization of Alzheimer's β-secretase protein BACE. A pepsin family member with unusual properties. J. Biol. Chem. (2000) 275(28):21099-21106.
212. BENNETT BD, DENIS P, HANIU M et al.: A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's β-secretase. J. Biol. Chem. (2000) 275(48):37712-37717.
213. SHI XP, CHEN E, YIN KC et al.: The pro domain of β-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. J. Biol. Chem. (2001) 276(13):10366-10373.
214. BENJANNET S, ELAGOZ A, WICKHAM L et al.: Post-translational processing of β-secretase (β-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activityand amyloid-β production. J. Biol. Chem. (2001) 276(14):10879-10887.
215. HUANG X-P, CHANG W-P, KOELSCH G et al.: Internalization of exogenously added memapsin 2 (β-secretase) ectodomain by cells Is mediated by amyloid precursor protein. J. Biol. Chem. (2004) 279(36):37886-37894.
216. HUSE JT, BYANT D, YANG Y et al.: Endoproteolysis of β-secretase (β-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. J. Biol. Chem. (2003) 278(19):17141-17149.
217. BENJANNET S, CROMLISH J, DIALLO K, CHRETIEN M, SEIDAH N: The metabolism of β-amyloid converting enzyme and β-amyloid precursor protein processing. Biochem. Biophys. Res. Commun. (2004) 325(1):235-242.
218. COLCIAGHI F, MARCELLO E, BORRONI B et al.: Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer's disease. Neurology (2004) 62(3):498-501.
219. GRUNINGER-LEITCH F, SCHLATTER D, KUNG E, NELBOCK P, DOBELI H: Substrate and inhibitor profile of BACE (β-secretase) and comparison with other mammalian aspartic proteases. J. Biol. Chem. (2002) 277(7):4687-4693.
220. TOMASSELLI AG, QAHWASH I, EMMONS TL et al.: Employing a superior BACE1 cleavage sequence to probe cellular APP processing. J. Neurochem. (2003) 84(5):1006-1017.
221. SHI X, TUGUSHEVA K, BRUCE J et al.: Novel mutations introduced at the β-site of amyloid β protein precursor enhance the production of amyloid β peptide by BACE1 in vitro and in cells. J. Alzheimers. Dis. (2005) 7(2):139-48.
222. TOULOKHONOVA L, METZLER WJ, WITMER MR, COPELAND RA, MARCINKEVICIENE J: Kinetic studies on β-site amyloid precursor protein-cleaving enzyme (BACE). Confirmation of an iso mechanism. J. Biol. Chem. (2003) 278(7):4582-4589.
223. NORTHROP DB: Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Acc. Chem. Res. (2001) 34(10):790-797.
224. PATEL S, VUILLARD L, CLEASBY A, MURRAY CW, YON J: Apo and Inhibitor Complex Structures of BACE (β-secretase). J. Mol. Biol. (2004) 343(2):407-416.
225. HONG L, HE X, HUANG X, CHANG W, TANG J: Structural features of human memapsin 2 (β-secretase) and their biological and pathological implications. Acta Biochim. Biophys. Sin. (2004) 36(12):787-792.
226. KOPCHO LM, MA J, MARCINKEVICIENE J et al.: Comparative studies of active site-ligand interactions among various recombinant constructs of human β-amyloid precursor protein cleaving enzyme. Arch. Biochem. Biophys. (2003) 410(2):307-316.
227. SIDERA C, LIU C, AUSTEN B: Pro-domain removal in ASP-2 and the cleavage of the amyloid precursor are influenced by pH. BMC Biochemistry (2002) 3(1):25.
228. SCHMECHEL A, STRAUSS M, SCHLICKSUPP A et al.: Human BACE Forms Dimers and Colocalizes with APP. J. Biol. Chem. (2004) 279(38):39710-39717.
229. WESTMEYER GG, WILLEM M, LICHTENTHALER SF et al.: Dimerization of β-site β-amyloid precursor protein-cleaving enzyme. J. Biol. Chem. (2004) 279(51):53205-53212.
230. MARLOW L, CAIN M, PAPPOLLA MA, SAMBAMURTI K: β-Secretase processing of the Alzheimer's amyloid protein precursor (APP). J. Mol. Neurosci. (2003) 20(3):233-239.
231. CUMMING JN, ISELOH U, KENNEDY ME: Design and development of BACE-1 inhibitors. Curr. Opin. Drug Discov. Devel. (2004) 7(4):536-556.
232. LARNER AJ: Secretases as therapeutic targets in Alzheimer's disease: patents 2000-2004. Expert Opin. Ther. Patents (2004) 14(10):1403-1420.
233. HUSSAIN I: The Potential for BACE1 inhibitors in the treatment of Alzheimer's disease. IDrugs (2004) 7(7):653-658.
234. CHANG W-P, KOELSCH G, WONG S et al.: In vivo inhibition of Ab production by memapsin 2 (b-secretase) inhibitors. J. Neurochem. (2004) 89(6):1409-1416.
235. GHOSH AK, DEVASAMUDRAM T, HONG L et al.: Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase). Bioorg. Med. Chem. Lett. (2005) 15(1):3576-3585.
236. TURNER RT, HONG L, KOELSCH G, CHOSH AK, TANG J: Structural locations and functional roles of new subsites S-5, S-6, and S-7 in memapsin 2 (P-secretase). Biochemistry (2005) 44(1):105-112
237. HONG L, TURNER RT, KOELSCH G et al.: Crystal structure of memapsin 2 (β-secretase) in complex with an inhibitor OM00-3. Biochemistry (2002) 41(36):10963-10967.
238. RIZZI L, ROMEO S: Inhibition of BACE-1 by hydroxyethylsulfide, hydroxyethylamine and hydroxyethylurea isosteric replacements. Lett. Drug Design Discov. (2005) 2(2):109-112.
239. HU B, FAN KY, BRIDGES K et al.: Synthesis and SAR of bis-statine based peptides as BACE1 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(13):3457-3460.
240. KIMURA T, SHUTO D, HAMADA Y et al.: Design and synthesis of highly active Alzheimer's (β)-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg. Med. Chem. Lett. (2005) 15(1):211-215.
241. COBURN CA, STACHEL SJ, LI YM et al.: Identification of a small molecule nonpeptide active site (β)-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J. Med. Chem. (2004) 47(25): 6117-6119.
242. STACHEL SJ, COBURN CA, STEELE TG et al.: Structure-based design of potent and selective cell-permeable inhibitors of human (β)-secretase (BACE-1). J. Med. Chem. (2004) 47(26):6447-6450
243. SCHOLEFIELD Z, YATES EA, WAYNE G et al.: Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's b-secretase. J. Cell Biol. (2003) 163(1):97-107.
244. DE MEYER GRY, DE CLEEN DMM, COOPER S et al.: Platelet phagocytosis and processing of b-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ. Res. (2002) 90(11):1197-1204.
245. VATTEMI G, ENGEL WK, McFERRIN J et al.: BACE1 and BACE2 in pathologic and normal human muscle. Exp. Neurol. (2003) 179(2):150-158.
246. PASTORINO L, IKIN AF, LAMPRIANOU S et al.: BACE (β-secretase) modulates the processing of APLP2 in vivo. Mol. Cell. Neurosci. (2004) 25(4):642-649.
247. LI Q, SUEDHOF TC: Cleavage of amyloid-β precursor protein and amyloid-β precursor-like protein by BACE 1. J. Biol. Chem. (2004) 279(11):10542-10550.
248. VON ARNIM CAF, KINOSHITA A, PELTAN ID et al.: The LDL-receptor related protein (LRP) is a novel β-secretase (BACE 1) substrate. J. Biol. Chem. (2005) 280(18):17777-17785
249. YOON I-S, PIETRZIK CU, KANG DE, KOO EH: Sequences from the LRP cytoplasmic domain enhances amyloid β-protein production via the β-secretase pathway without altering APP/LRP nuclear signaling. J. Biol. Chem. (2005) 280(20):20140-20147
250. LICHTENTHALER S, DOMINGUEZ D, WESTMEYER G et al.: The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. (2003) 278(49):48713-48719.
251. KITAZUME S, TACHIDA Y, OKA R et al.: Alzheimer's β-secretase, β-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc. Natl. Acad. Sci. USA (2001) 98(24):13554-13559.
252. KITAZUME S, TACHIDA Y, OKA R et al.: Characterization of α2,6sialyltransferase cleavage by Alzheimer's β-secretase (BACE1). J. Biol. Chem. (2003) 278(17):14865-14871.
253. KITAZUME S, NAKAGAWA K, OKA R et al.: In vivo cleavage of α 2,6-sialyltransferase by Alzheimer β-secretase. J. Biol. Chem. (2005) 280(9):8589-8595.
254. WEIHOFEN A, LEMBERG MK, FRIEDMANN E et al.: Targeting presenilin-type aspartic protease signal peptide peptidase with γ-secretase inhibitors. J. Biol. Chem. (2003) 278(19):16528-16533.
255. LAMMICH S, KOJRO E, POSTINA R et al.: Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. USA (1999) 96(7):3922-3927.
256. GHISO J, SHAYO, M, CALERO M et al.: Systemic catabolism of Alzheimer's Aβ40 and Aβ42. J. Biol. Chem. (2004) 279(44):45897-45908.
257. DOAN A, THINAKARAN G, BORCHELT DR et al.: Protein topology of presenilin 1. Neuron (1996) 17(5):1023-1030.
258. FORTNA RR, CRYSTAL AS, MORAIS VA et al.: Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the γ-secretase complex. J. Biol. Chem. (2004) 279(5):3685-3693.
259. CRYSTAL AS, MORAIS VA, PIERSON TC et al.: Membrane topology of γ-secretase component PEN-2. J. Biol. Chem. (2003) 278(22):20117-20123.
260. THINAKARAN G, BORCHELT DR, LEE MK et al.: Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 17(1):181-190.
261. DUNN BM: Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem. Rev. (2002) 102(12):4431-4458.
262. TYNDALL JD, NALL T, FAIRLIE DP: Proteases universally recognize β strands in their active sites. Chem. Rev. (2005) 105(3):973-999.
263. LI M, PHYLIP LH, LEES WE et al.: The aspartic proteinase from Saccharomyces cerevisiae folds its own inhibitor into a helix. Nat. Struct. Biol. (2000) 7(12):113-117.